Carlyle and SK Capital Partners have announced an extension to their tender offer for bluebird bio, Inc., moving the expiration date to one minute after 11:59 p.m. New York City time on May 2, 2025. The offer was initially set to expire on April 18, 2025. This extension is to allow more time to meet the remaining conditions of the offer, which include obtaining necessary regulatory approvals.
As per Equiniti Trust Company, LLC, the depositary for the offer, approximately 700,288 shares of bluebird common stock have been validly tendered and not withdrawn as of April 15, 2025. Those who have already tendered shares do not need to take further action in response to this extension.
The tender offer aligns with the terms outlined in the "Offer to Purchase" dated March 7, 2025. This includes various conditions such as the tender of a majority of outstanding shares, regulatory approvals, and other customary conditions.
Equiniti Trust Company's advice to Merger Sub indicates significant participation in the offer. This communication is not a solicitation to buy or sell any securities of bluebird. All related documentation has been filed with the U.S. Securities and Exchange Commission (SEC).
The offer has been structured following the tender offer statement on Schedule TO filed by Beacon Parent Holdings, L.P., and Beacon Merger Sub, Inc. on March 7, 2025. Related documents filed by bluebird include a Solicitation/Recommendation Statement on Schedule 14D-9.
Carlyle is a global investment firm, managing $441 billion in assets as of the end of 2024 across various business segments. SK Capital focuses on life sciences, specialty materials, and ingredients sectors, managing about $9 billion in assets with operations spanning over 30 countries.
Stakeholders and investors are advised to examine these documents carefully before deciding on whether to tender their shares, as they contain critical information about the offer.
Further contact details for investor and media relations at bluebird, Carlyle, and SK Capital were provided in the announcement.